Skip to main content
. Author manuscript; available in PMC: 2021 Oct 12.
Published in final edited form as: ACS Biomater Sci Eng. 2020 Sep 10;6(10):5941–5958. doi: 10.1021/acsbiomaterials.0c01075

Figure 3. High dose GM-CSF and TGF-b1 in the udMP do not prevent diabetes in 8-week-old NOD mice compared to blank MPs.

Figure 3.

A cohort of 8-week-old NOD mice (n = 15/group) were injected at a subcutaneous site anatomically proximal to the pancreas with the described MP formulations over 16 weeks. Animals received MP injections (arrows) once a week for the first three weeks (8, 9 and 10 weeks of age) and a booster injection once monthly thereafter for four months (12, 16, 20, and 24 weeks of age). Blank MPs were included as a control treatment group. Animals were monitored weekly until week 28, after which remaining non-diabetic mice were euthanized, and mice were considered diabetic when blood glucose levels were ≥ 240 mg/dL on two consecutive days. Survival data is fit using the Kaplan–Meier non-parametric survival analysis model and statistical analysis (p-value = 0.21) performed via log-rank test (Mantel-Cox method).